Literature DB >> 26429976

High ΔNp73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia.

Antonio R Lucena-Araujo1, Haesook T Kim2, Carolina Thomé1, Rafael H Jacomo1, Raul A Melo3, Rosane Bittencourt4, Ricardo Pasquini5, Katia Pagnano6, Ana Beatriz F Glória7, Maria de Lourdes Chauffaille8, Melina Athayde7, Carlos S Chiattone9, Ingrid Mito4, Rodrigo Bendlin5, Carmino Souza6, Cristina Bortolheiro9, Juan L Coelho-Silva10, Stanley L Schrier11, Martin S Tallman12, David Grimwade13, Arnold Ganser14, Nancy Berliner15, Raul C Ribeiro16, Francesco Lo-Coco17, Bob Löwenberg18, Miguel A Sanz19, Eduardo M Rego1.   

Abstract

The TP73 gene transcript is alternatively spliced and translated into the transcriptionally active (TAp73) or inactive (ΔNp73) isoforms, with opposite effects on the expression of p53 target genes and on apoptosis induction. The imbalance between ΔNp73 and TAp73 may contribute to tumorigenesis and resistance to chemotherapy in human cancers, including hematologic malignancies. In acute promyelocytic leukemia (APL), both isoforms are expressed, but their relevance in determining response to therapy and contribution to leukemogenesis remains unknown. Here, we provide the first evidence that a higher ΔNp73/TAp73 RNA expression ratio is associated with lower survival, lower disease-free survival, and higher risk of relapse in patients with APL homogeneously treated with all-trans retinoic acid and anthracycline-based chemotherapy, according to the International Consortium on Acute Promyelocytic Leukemia (IC-APL) study. Cox proportional hazards modeling showed that a high ΔNp73/TAp73 ratio was independently associated with shorter overall survival (hazard ratio, 4.47; 95% confidence interval, 1.64-12.2; P = .0035). Our data support the hypothesis that the ΔNp73/TAp73 ratio is an important determinant of clinical response in APL and may offer a therapeutic target for enhancing chemosensitivity in blast cells.
© 2015 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26429976      PMCID: PMC4760128          DOI: 10.1182/blood-2015-01-623330

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  28 in total

1.  DeltaNp73 stabilises TAp73 proteins but compromises their function due to inhibitory hetero-oligomer formation.

Authors:  N Slade; A I Zaika; S Erster; U M Moll
Journal:  Cell Death Differ       Date:  2004-03       Impact factor: 15.828

Review 2.  Negative autoregulation of p73 and p53 by DeltaNp73 in regulating differentiation and survival of human neuroblastoma cells.

Authors:  Takahito Nakagawa; Masato Takahashi; Toshinori Ozaki; Ken-ichi Watanabe; Shunji Hayashi; Mitsuchika Hosoda; Satoru Todo; Akira Nakagawara
Journal:  Cancer Lett       Date:  2003-07-18       Impact factor: 8.679

3.  p53 induces the expression of its antagonist p73 Delta N, establishing an autoregulatory feedback loop.

Authors:  Natalia N Kartasheva; Ana Contente; Claudia Lenz-Stöppler; Judith Roth; Matthias Dobbelstein
Journal:  Oncogene       Date:  2002-07-18       Impact factor: 9.867

4.  Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.

Authors:  Antonio R Lucena-Araujo; Haesook T Kim; Rafael H Jacomo; Raul A Melo; Rosane Bittencourt; Ricardo Pasquini; Katia Pagnano; Evandro M Fagundes; Maria de Lourdes Chauffaille; Carlos S Chiattone; Ana Silvia Lima; Guillermo Ruiz-Argüelles; Maria Soledad Undurraga; Lem Martinez; Hau C Kwaan; Robert Gallagher; Charlotte M Niemeyer; Stanley L Schrier; Martin S Tallman; David Grimwade; Arnold Ganser; Nancy Berliner; Raul C Ribeiro; Francesco Lo-Coco; Bob Löwenberg; Miguel A Sanz; Eduardo M Rego
Journal:  Ann Hematol       Date:  2014-07-02       Impact factor: 3.673

5.  Evaluating the yield of medical tests.

Authors:  F E Harrell; R M Califf; D B Pryor; K L Lee; R A Rosati
Journal:  JAMA       Date:  1982-05-14       Impact factor: 56.272

6.  An anti-apoptotic role for the p53 family member, p73, during developmental neuron death.

Authors:  C D Pozniak; S Radinovic; A Yang; F McKeon; D R Kaplan; F D Miller
Journal:  Science       Date:  2000-07-14       Impact factor: 47.728

7.  Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73.

Authors:  Osamu Ishimoto; Chikashi Kawahara; Kentaro Enjo; Masuo Obinata; Toshihiro Nukiwa; Shuntaro Ikawa
Journal:  Cancer Res       Date:  2002-02-01       Impact factor: 12.701

8.  Frequency of RAS and p53 mutations in acute promyelocytic leukemias.

Authors:  L Longo; D Trecca; A Biondi; F Lo Coco; F Grignani; A T Maiolo; P G Pelicci; A Neri
Journal:  Leuk Lymphoma       Date:  1993-11

9.  Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53.

Authors:  T J Grob; U Novak; C Maisse; D Barcaroli; A U Lüthi; F Pirnia; B Hügli; H U Graber; V De Laurenzi; M F Fey; G Melino; A Tobler
Journal:  Cell Death Differ       Date:  2001-12       Impact factor: 15.828

10.  DNA damage induces the rapid and selective degradation of the DeltaNp73 isoform, allowing apoptosis to occur.

Authors:  C Maisse; E Munarriz; D Barcaroli; G Melino; V De Laurenzi
Journal:  Cell Death Differ       Date:  2004-06       Impact factor: 15.828

View more
  14 in total

1.  Combining gene mutation with gene expression analysis improves outcome prediction in acute promyelocytic leukemia.

Authors:  Antonio R Lucena-Araujo; Juan L Coelho-Silva; Diego A Pereira-Martins; Douglas R Silveira; Luisa C Koury; Raul A M Melo; Rosane Bittencourt; Katia Pagnano; Ricardo Pasquini; Elenaide C Nunes; Evandro M Fagundes; Ana B Gloria; Fábio Kerbauy; Maria de Lourdes Chauffaille; Israel Bendit; Vanderson Rocha; Armand Keating; Martin S Tallman; Raul C Ribeiro; Richard Dillon; Arnold Ganser; Bob Löwenberg; P J M Valk; Francesco Lo-Coco; Miguel A Sanz; Nancy Berliner; Eduardo M Rego
Journal:  Blood       Date:  2019-07-10       Impact factor: 22.113

2.  Clinical impact of BAALC expression in high-risk acute promyelocytic leukemia.

Authors:  Antonio R Lucena-Araujo; Diego A Pereira-Martins; Luisa C Koury; Pedro L Franca-Neto; Juan L Coelho-Silva; Virginia M de Deus Wagatsuma; Raul A M Melo; Rosane Bittencourt; Katia Pagnano; Ricardo Pasquini; Carlos S Chiattone; Evandro M Fagundes; Maria de Lourdes Chauffaille; Stanley L Schrier; Martin S Tallman; Raul C Ribeiro; David Grimwade; Arnold Ganser; Bob Löwenberg; Francesco Lo-Coco; Miguel A Sanz; Nancy Berliner; Eduardo M Rego
Journal:  Blood Adv       Date:  2017-09-15

Review 3.  Clinical implications of the deregulated TP73 isoforms expression in cancer.

Authors:  N Rodríguez; A Peláez; R Barderas; G Domínguez
Journal:  Clin Transl Oncol       Date:  2017-12-11       Impact factor: 3.405

4.  Overexpression of splicing factor poly(rC)-binding protein 1 elicits cycle arrest, apoptosis induction, and p73 splicing in human cervical carcinoma cells.

Authors:  Yuhong Chen; Zhihui Dou; Xiaohua Chen; Dapeng Zhao; Tuanjie Che; Wei Su; Tao Qu; Taotao Zhang; Caipeng Xu; Huiweng Lei; Qiang Li; Hong Zhang; Cuixia Di
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-27       Impact factor: 4.322

5.  Use of signals of positive and negative selection to distinguish cancer genes and passenger genes.

Authors:  László Bányai; Maria Trexler; Krisztina Kerekes; Orsolya Csuka; László Patthy
Journal:  Elife       Date:  2021-01-11       Impact factor: 8.140

6.  The landscape and biological relevance of aberrant alternative splicing events in esophageal squamous cell carcinoma.

Authors:  Quanyou Wu; Yuan Zhang; Haiyin An; Wei Sun; Ruozheng Wang; Meng Liu; Kaitai Zhang
Journal:  Oncogene       Date:  2021-06-02       Impact factor: 9.867

7.  ΔNp73 overexpression promotes resistance to apoptosis but does not cooperate with PML/RARA in the induction of an APL-leukemic phenotype.

Authors:  Antonio R Lucena-Araujo; Juan L Coelho-Silva; Diego A Pereira-Martins; Carolina Thomé; Priscila S Scheucher; Ana P Lange; Helder H Paiva; Benjamin T Hemmelgarn; Mariana C Morais-Sobral; Elisa A Azevedo; Pedro L Franca-Neto; Rafael F Franca; Cleide L Silva; Alexandre Krause; Eduardo M Rego
Journal:  Oncotarget       Date:  2017-01-31

8.  NTAL is associated with treatment outcome, cell proliferation and differentiation in acute promyelocytic leukemia.

Authors:  Carolina Hassibe Thomé; Germano Aguiar Ferreira; Diego Antonio Pereira-Martins; Vitor Marcel Faça; Eduardo M Rego; Guilherme Augusto Dos Santos; César Alexander Ortiz; Lucas Eduardo Botelho de Souza; Lays Martins Sobral; Cleide Lúcia Araújo Silva; Priscila Santos Scheucher; Cristiane Damas Gil; Andréia Machado Leopoldino; Douglas R A Silveira; Juan L Coelho-Silva; Fabíola Traina; Luisa C Koury; Raul A M Melo; Rosane Bittencourt; Katia Pagnano; Ricardo Pasquini; Elenaide C Nunes; Evandro M Fagundes; Ana Beatriz F Gloria; Fábio Rodrigues Kerbauy; Maria de Lourdes Chauffaille; Armand Keating; Martin S Tallman; Raul C Ribeiro; Richard Dillon; Arnold Ganser; Bob Löwenberg; Peter Valk; Francesco Lo-Coco; Miguel A Sanz; Nancy Berliner
Journal:  Sci Rep       Date:  2020-06-25       Impact factor: 4.379

9.  ΔNp73, TAp73 and Δ133p53 Extracellular Vesicle Cargo as Early Diagnosis Markers in Colorectal Cancer.

Authors:  Javier Rodríguez-Cobos; David Viñal; Carmen Poves; María J Fernández-Aceñero; Héctor Peinado; Daniel Pastor-Morate; Mª Isabel Prieto; Rodrigo Barderas; Nuria Rodríguez-Salas; Gemma Domínguez
Journal:  Cancers (Basel)       Date:  2021-05-07       Impact factor: 6.639

Review 10.  Oncogenic Intra-p53 Family Member Interactions in Human Cancers.

Authors:  Maria Ferraiuolo; Silvia Di Agostino; Giovanni Blandino; Sabrina Strano
Journal:  Front Oncol       Date:  2016-03-31       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.